Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma: The Effectiveness of Different Particle Sizes in Downstaging and Bridging in Living Donor Liver Transplantation

• Published in: Transplantation proceedings Vol. 56; no. 3; pp. 596 - 601
• Main Authors: Lim, Wei-Xiong, Sim, Kuan Siong, Chen, Chao-Long, Ou, Hsin-You, Yu, Chun-Yen, Cheng, Yu-Fan
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.04.2024
• ISSN: 0041-1345; 1873-2623
• DOI: 10.1016/j.transproceed.2024.01.062

•Drug-eluting bead transarterial chemoembolization (TACE) treatment is associated with a good downstaging rate for pretransplant patients.•Drug-eluting bead TACE treatment provides another treatment option for bridging and downstaging treatment among pretransplant hepatocellular patients besides conventional TACE and radiofrequency ablation.•Successful living donor liver transplantation improved long-term survival rate for patients with hepatocellular carcinoma post-transplant. To compare the effectiveness of drug-eluting bead transarterial chemoembolization (DEB-TACE) with different particle sizes in bridging and downstaging in pretransplant hepatocellular carcinoma patients. Assess the recurrent and survival rates after living donor liver transplantation (LDLT). Retrospective review of 580 patients who underwent TACE using DEB from August 2012 to June 2020 at Taiwan Kaohsiung Chang Gung Memorial Hospital. Pre- and post-TACE computed tomography scan images of the liver were reviewed, and treatment responses were assessed using modified Response Evaluation Criteria in Solid Tumors criteria. Patients were divided by who met the criteria (n = 342) or beyond (n = 238) the University of California San Francisco criteria for successful bridging and downstaging rate evaluation. Each group was divided into subgroups according to DEB particle sizes (group A: <100μm, group B: 100-300 μm, group C: 300-500 μm, and group D: 500-700 μm) to compare objective response rate and post-LDLT survival rate. Overall successful bridging and downstaging rate is 97.1% and 58.4%, respectively, in the group of patients who meet the criteria (n = 332) and are beyond (n = 139) the University of California San Francisco criteria. Group B (100-300 μm) had a higher successful bridging rate (99.5%, P = .003) and downstaging rate (63.8%, P = .443). This subgroup also demonstrated a higher objective response rate in single (93.2%, P = .038) tumors, multiple (83.3%, P = .001) tumors, and tumors with size less than 5 cm (93.9%, P = .005). There are no significant differences in post-LDLT overall survival rate between different particle sizes. TACE with 100 to 300 μm DEB particles is associated with a better chance of bridging and downstaging hepatocellular carcinoma patients to LDLT.